You shouldn't have to choose between protecting your privacy and paying a fair price
Court found Drogasil's CPF requirement for discounts constitutes coercive, unfair commercial practice prohibited by Consumer Protection Code. Judge ruled the practice exploits healthcare necessity and medication price sensitivity to build customer databases, violating good faith commercial principles.
- Drogasil ordered to pay R$10 million in damages by Maranhão State Court of Justice
- Court ruled CPF requirement for discounts violates Consumer Protection Code
- Damages will fund State Fund for Protection of Diffuse Rights
- Decision issued Tuesday, June 2; appeal status unclear
Brazilian court condemns Drogasil pharmacy to R$10 million in damages for requiring CPF data to access discounts, ruling the practice violates consumer protection laws and penalizes privacy rights.
A pharmacy chain in Brazil has been ordered to pay ten million reais in damages for a practice that seemed small but cut to something larger: making discounts conditional on handing over personal information. The Maranhão State Court of Justice issued the ruling on Tuesday, finding that Drogasil had systematically used the promise of savings to pressure customers into surrendering their CPF numbers—Brazil's equivalent of a Social Security number—or lose the discount entirely.
The judge's reasoning was straightforward and damning. When a customer refuses to provide their data, the pharmacy cannot punish them by withdrawing a discount they would otherwise receive. That's coercion dressed up as commerce. The court classified the practice as an unfair and coercive sales method, one that violates the Consumer Protection Code. More than that, it penalizes people economically simply for exercising their right to privacy. The logic is simple: you shouldn't have to choose between protecting your personal information and paying a fair price for medicine.
What made this case resonate with the court was the context in which it occurred. A pharmacy isn't selling luxury goods or entertainment. It's selling access to healthcare. Medications are often expensive, and price sensitivity runs high—people need these products, sometimes urgently. The judge found that Drogasil had weaponized that necessity. By tying discounts to data collection, the company was using people's basic need for affordable medicine as leverage to inflate its customer database. That's not just aggressive marketing; it's an abuse of power.
The court also characterized the arrangement as an indirect form of "tied selling"—a practice where you're forced to buy one thing to get another—which the Consumer Protection Code explicitly forbids. The ruling added that the practice represented an excessive advantage taken by the company, another violation of consumer law. The judge's language grew sharper here, describing Drogasil's conduct as a "patent abuse of right" and a violation of the good faith that should govern commercial relationships. In other words, this wasn't a gray area. It was a clear breach.
The ten million reais in damages will go to the State Fund for the Protection of Diffuse Rights, a pool of money used to support consumer protection efforts across Maranhão. The court has not yet clarified whether the decision can be appealed, leaving some uncertainty about whether this ruling will stand as final or face further challenge. That ambiguity matters: if the decision holds, it could reshape how retailers across Brazil think about data collection at the point of sale. If it's overturned, the question of whether pharmacies can condition discounts on personal information remains unsettled.
Citações Notáveis
The company used the necessity of healthcare access and medication price sensitivity as tools of pressure to inflate its customer database, constituting a patent abuse of right and violation of good faith in commercial relations— Maranhão State Court of Justice ruling
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter that this was a pharmacy specifically, rather than any other retailer?
Because medicine isn't optional. A grocery store sells food you need, but you can shop elsewhere. A pharmacy in many neighborhoods is the only place to get your prescription filled. When you're sick or managing a chronic condition, you're not in a position to walk away. That's the leverage Drogasil exploited.
The court called this "tied selling." How is requiring a CPF for a discount the same as forcing you to buy two things?
It's indirect. You're not forced to buy a second product, but you are forced to make a choice: give up your data or pay full price. The effect is the same—you can't get the benefit without surrendering something you didn't agree to give. The court saw through the disguise.
What happens to the data that was already collected this way?
The ruling doesn't address that. It stops the practice going forward, but it doesn't undo what's already in Drogasil's database. That's a gap in the decision.
If this can be appealed, what's the pharmacy's likely argument?
Probably that data collection is standard retail practice, that customers benefit from personalized offers, and that no one was forced—they could simply refuse the discount. The court rejected that logic, but it's the argument you'd expect.
Does this change anything for other companies doing the same thing?
Not yet. This is one state court ruling. But if it holds up on appeal, retailers across Brazil will have to rethink how they tie discounts to data. That's why the appeal question matters so much.